AAUM (Average Assets Under Management) of ₹3,414.29 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 74.8% | 75.8% | ▲ +1.0% |
| Healthcare Services | 22.9% | 20.5% | ▼ -2.4% |
| Chemicals & Petrochemicals | 1.1% | 1.9% | ▲ +0.9% |
| Healthcare Equipment & Supplies | 0.0% | 1.8% | ▲ +1.8% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 75.8% | 75.9% | ● +0.1% |
| Healthcare Services | 20.5% | 20.5% | ● +0.0% |
| Chemicals & Petrochemicals | 1.9% | 1.8% | ▼ -0.1% |
| Healthcare Equipment & Supplies | 1.8% | 1.7% | ● -0.1% |
Comparing Sep 2026 → Oct 2026
| # | Stock | Sector | Last Weight (Sep 2026) |
|---|---|---|---|
| 1 | Anthem Biosciences Limited ₹32.45 Cr |
Pharmaceuticals & Biotechnology | 0.93% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Laurus Labs Limited ₹226.78 Cr |
Pharmaceuticals & Biotechnology | 5.51% | 6.37% | +0.86% |
| 2 | Dr. Reddy's Laboratories Limited ₹194.23 Cr |
Pharmaceuticals & Biotechnology | 4.84% | 5.45% | +0.61% |
| 3 | Apollo Hospitals Enterprise Limited ₹206.85 Cr |
Healthcare Services | 5.62% | 5.81% | +0.19% |
| 4 | Divi's Laboratories Limited ₹355.19 Cr |
Pharmaceuticals & Biotechnology | 9.79% | 9.97% | +0.18% |
| 5 | Sun Pharmaceutical Industries Limited ₹367.47 Cr |
Pharmaceuticals & Biotechnology | 10.15% | 10.32% | +0.17% |
| 6 | Dr. Lal Path Labs Limited ₹108.66 Cr |
Healthcare Services | 2.90% | 3.05% | +0.15% |
| 7 | Gland Pharma Limited ₹100.29 Cr |
Pharmaceuticals & Biotechnology | 2.69% | 2.82% | +0.13% |
| 8 | Krishna Institute Of Medical Sciences Limited ₹123.98 Cr |
Healthcare Services | 3.39% | 3.48% | +0.09% |
| 9 | Symbiotec Pharmalab Limited ₹59.11 Cr |
Pharmaceuticals & Biotechnology | 1.60% | 1.66% | +0.06% |
| 10 | Onesource Specialty Pharma Limited ₹108.14 Cr |
Pharmaceuticals & Biotechnology | 3.01% | 3.04% | +0.03% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Torrent Pharmaceuticals Limited ₹228.46 Cr |
Pharmaceuticals & Biotechnology | 6.80% | 6.41% | -0.39% |
| 2 | Max Healthcare Institute Limited ₹75.81 Cr |
Healthcare Services | 2.35% | 2.13% | -0.22% |
| 3 | Glenmark Pharmaceuticals Limited ₹164.38 Cr |
Pharmaceuticals & Biotechnology | 4.78% | 4.61% | -0.17% |
| 4 | Aster DM Healthcare Limited ₹113.51 Cr |
Healthcare Services | 3.32% | 3.19% | -0.13% |
| 5 | Eris Lifesciences Limited ₹80.90 Cr |
Pharmaceuticals & Biotechnology | 2.39% | 2.27% | -0.12% |
| 6 | Alkem Laboratories Limited ₹130.08 Cr |
Pharmaceuticals & Biotechnology | 3.76% | 3.65% | -0.11% |
| 7 | Neogen Chemicals Limited ₹50.22 Cr |
Chemicals & Petrochemicals | 1.50% | 1.41% | -0.09% |
| 8 | Molbio Diagnostics Ltd. ₹60.24 Cr |
Healthcare Equipment & Supplies | 1.77% | 1.69% | -0.08% |
| 9 | Lupin Limited ₹78.46 Cr |
Pharmaceuticals & Biotechnology | 2.27% | 2.20% | -0.07% |
| 10 | Fortis Healthcare Limited ₹102.40 Cr |
Healthcare Services | 2.94% | 2.87% | -0.07% |
28 stocks — Oct 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹367.47 Cr |
Pharmaceuticals & Biotechnology |
10.32%
|
|
| 2 |
₹355.19 Cr |
Pharmaceuticals & Biotechnology |
9.97%
|
|
| 3 |
₹228.46 Cr |
Pharmaceuticals & Biotechnology |
6.41%
|
|
| 4 |
₹226.78 Cr |
Pharmaceuticals & Biotechnology |
6.37%
|
|
| 5 |
₹206.85 Cr |
Healthcare Services |
5.81%
|
|
| 6 |
₹194.23 Cr |
Pharmaceuticals & Biotechnology |
5.45%
|
|
| 7 |
₹164.38 Cr |
Pharmaceuticals & Biotechnology |
4.61%
|
|
| 8 |
₹132.72 Cr |
Pharmaceuticals & Biotechnology |
3.73%
|
|
| 9 |
₹130.08 Cr |
Pharmaceuticals & Biotechnology |
3.65%
|
|
| 10 |
₹123.98 Cr |
Healthcare Services |
3.48%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.